- Consenso SEIP-SENP sobre el diagnóstico de la tuberculosis en la edad pediátrica
- Tratamiento de las infecciones por estafilococo dorado resistentes a la meticilina
- Plasmaféresis en desórdenes neurológicos.
- Manejo clínico de los síndromes mielodisplásicos
- Diagnóstico de la tuberculosis en la edad pediátrica.
Documento de consenso de la Sociedad Española de Infectologıá Pediátrica (SEIP) y la Sociedad Española de Neumología Pediátrica (SENP)
- Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children: Executive Summary
- Evidence-based guideline update: Plasmapheresis in neurologic disorders : Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
- Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines
Consenso SEIP-SENP sobre el diagnóstico de la tuberculosis en la edad pediátrica
Consenso SEIP-SENP sobre el diagnóstico de la tuberculosis en la edad pediátrica An Pediatr (Barc).2010;73(3):143.e1–143.e14
Resumen La tuberculosis continúa siendo uno de los problemas sanitarios más importantes en el mundo. En países desarrollados se está´ asistiendo a un aumento de casos, incluidos los niños, por diferentes motivos. El más determinante parece ser la inmigración procedente de zonas con elevada endemia de tuberculosis.
La tuberculosis (TB) continúa siendo un problema de magnitud mundial, planteando un verdadero reto para la medicina, debido al aumento de su incidencia en nuestro medio, así como a la emergencia de cepas resistentes. En la edad pediátrica, las dificultades añadidas más importantes son: a) una mayor probabilidad de progresión desde la infección a la enfermedad, incluidas formas graves y extrapulmonares; b) los problemas diagnósticos, incluyendo la dificultad para discernir entre infección y enfermedad, el difícil aislamiento microbiológico, y c) las dificultades terapéuticas por los escasos estudios, sobre todo con fármacos de segunda línea, la escasez de formulaciones pediátricas y la problemática de la cumplimentación del tratamiento.
Tratamiento de las infecciones por estafilococo dorado resistentes a la meticilina
Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE,Rybak MJ,Talan DA Chambers HF. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children: Executive Summary Clinical Infectious Diseases 2011;52(3):285–292
Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). The guidelines are intended for use by health care providers who care for adult and pediatric patients with MRSA infections. The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections. Recommendations are provided regarding vancomycin dosing and monitoring, management of infections due to MRSA strains with reduced susceptibility to vancomycin, and vancomycin treatment failures.
Plasmaféresis en desórdenes neurológicos
I. Cortese, V. Chaudhry, Y.T. So, F. Cantor, D.R. Cornblath.
A. Rae-Grant. Evidence-based guideline update: Plasmapheresis in neurologic disorders
Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology® 2011;76: 294–300
ABSTRACT
Objective: To reassess the role of plasmapheresis in the treatment of neurologic disorders.
Methods: We evaluated the available evidence based on a structured literature review for relevant articles from 1995 through September 2009. In addition, due to revision of the definitions of classification of evidence since the publication of the previous American Academy of Neurology assessment in 1996, the evidence cited in that manuscript was reviewed and reclassified.
Results and Recommendations: Plasmapheresis is established as effective and should be offered in severe acute inflammatory demyelinating polyneuropathy (AIDP)/Guillain-Barre´ syndrome (GBS) and in the short-term management of chronic inflammatory demyelinating polyneuropathy (Class I studies, Level A). Plasmapheresis is established as ineffective and should not be offered for chronic or secondary progressive multiple sclerosis (MS) (Class I studies, Level A). Plasmapheresis is probably effective and should be considered for mild AIDP/GBS, as second-line treatment of steroid-resistant exacerbations in relapsing forms of MS, and for neuropathy associated with immunoglobulin A or immunoglobulin G gammopathy, based on at least one Class I or 2 Class II studies (Level B). Plasmapheresis is probably not effective and should not be considered for neuropathy associated with immunoglobulinMgammopathy, based on one Class I study (Level B). Plasmapheresis is possibly effective and may be considered for acute fulminant demyelinating CNS disease (Level C). There is insufficient evidence to support or refute the use of plasmapheresis for myasthenia gravis, pediatric autoimmune neuropsychiatric disorders associated with streptococcus infection, and Sydenham chorea.
Manejo clínico de los síndromes mielodisplásicos
V. Santini, P.E. Alessandrinob, E. Angelucci, G. Barosi, A. Billio, M. Di Maiof, C. Finelli , F. Locatelli, M. Marchettii, E. Morra, P. Musto, G. Visanil, S. Turag Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines Leukemia Research 34 (2010) 1576–1588
a b s t r a c t
Since 2002, date of publication of the previous Italian Society of Haematology (SIE) practice guidelines for management of myelodysplastic syndromes (MDS), novel disease-modifying treatments have been introduced and the SIE commissioned an update.
After a comprehensive review of the medical literature published since January 2001, the Expert Panel formulated recommendations for the management of adult and paediatric MDS, graded according to the available evidence.
The major updates are: first-line hypomethylating agents in patients with INT2-high-risk disease; controlled use of first-line lenalidomide in low-INT1 risk transfusion-dependent patients with 5q deletion; deferasirox in low-INT1 patients with a relevant transfusional load; first-line high-dose ESA in low-INT1 patients with Hb <10 g/dl and endogenous EPO <500 U/l; allogeneic HSCT first-line therapy for INT2- and high-risk patients <65 years without severe co morbidities.
Diagnóstico de la tuberculosis en la edad pediátrica. Documento de consenso de la Sociedad Española de Infectologıá Pediátrica (SEIP) y la Sociedad Española de Neumología Pediátrica (SENP).
DESCARGAR PDF
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children: Executive SummarY.
DESCARGAR PDF
Evidence-based guideline update: Plasmapheresis in neurologic disorders : Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
DESCARGAR PDF
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.
DESCARGAR PDF
